PTCT vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, ASND, QGEN, BPMC, and BBIO
Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.
PTC Therapeutics vs. Its Competitors
Intra-Cellular Therapies (NASDAQ:ITCI) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.
PTC Therapeutics has a net margin of 33.56% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat PTC Therapeutics' return on equity.
Intra-Cellular Therapies has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.
92.3% of Intra-Cellular Therapies shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, PTC Therapeutics had 3 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 4 mentions for PTC Therapeutics and 1 mentions for Intra-Cellular Therapies. PTC Therapeutics' average media sentiment score of 1.43 beat Intra-Cellular Therapies' score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the news media.
Intra-Cellular Therapies currently has a consensus target price of $109.70, suggesting a potential downside of 16.81%. PTC Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 33.88%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe PTC Therapeutics is more favorable than Intra-Cellular Therapies.
Intra-Cellular Therapies has higher earnings, but lower revenue than PTC Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
PTC Therapeutics beats Intra-Cellular Therapies on 12 of the 17 factors compared between the two stocks.
Get PTC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTC Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PTCT) was last updated on 7/13/2025 by MarketBeat.com Staff
Free PTCT Stock Alerts